悦心健康(002162) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders to be between 2 million and 3 million yuan, representing a decline of 98.22% to 98.81% compared to the same period last year, where the profit was 168.545 million yuan[9]. - The company's operating revenue is projected to be between 500 million and 600 million yuan, down from 567.3225 million yuan in the same period last year[9]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of 14 million to 18 million yuan, compared to a profit of 7.174 million yuan in the previous year[9]. - Basic earnings per share are anticipated to be between 0.0022 yuan and -0.0032 yuan, compared to 0.1819 yuan per share last year[9]. Market Conditions - The decline in performance is attributed to reduced market demand in the tile business and intensified market competition, leading to lower sales prices and gross margins[6]. Corporate Actions - The company transferred the equity of its wholly-owned subsidiary, Shanghai Yueshin Health Technology Development Co., Ltd., in the first half of 2023, generating a related gain of 162 million yuan, with no similar transactions in the current reporting period[10]. Investor Guidance - The actual financial data for the first half of 2024 will be detailed in the company's half-year report[7]. - The company advises investors to make cautious decisions and be aware of investment risks due to the preliminary nature of the earnings forecast[7].